Opinion

Video

Exploring Biomarker Testing and Personalized Treatments in Breast Cancer

William J. Gradishar, MD, analyzes current guidelines for identifying targetable mutations in breast cancer, explores strategies to enhance biomarker testing for mutations like PIK3CA or AKT1, and anticipates the growing influence of personalized medicine on the future of breast cancer treatment.

  1. What are the current guidelines for testing for targetable mutations in breast cancer, and how widely are they followed in clinical practice? How can biomarker testing for targetable mutations, such as PIK3CA or AKT1, be improved or streamlined?
    1. How accessible are these biomarker tests in community oncology? 
  2. How is personalized medicine expected to impact the future use of targeted therapies (such as the PI3K pathway inhibitors) in breast cancer? What developments are needed to fully realize its potential?
Related Videos
2 experts in this video
Dr Chun Chao
1 expert is featured in this series.
Dr Chun Chao
5 experts are featured in this series.
5 experts are featured in this series.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo